Tarceva Monotherapy Shows Survival Benefit, Differentiates Oncologic From Iressa – Genentech

Genentech/OSI project summer filing and Q1 2005 launch following positive findings from a pivotal monotherapy study. The refractory NSCLC study is slated for presentation at the American Society of Clinical Oncology meeting in June.